CN101801415B - 利培酮化合物的持续递送制剂 - Google Patents

利培酮化合物的持续递送制剂 Download PDF

Info

Publication number
CN101801415B
CN101801415B CN200880100394.0A CN200880100394A CN101801415B CN 101801415 B CN101801415 B CN 101801415B CN 200880100394 A CN200880100394 A CN 200880100394A CN 101801415 B CN101801415 B CN 101801415B
Authority
CN
China
Prior art keywords
risperidone
implant
release
day
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880100394.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN101801415A (zh
Inventor
埃里克·达代
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
British Virgin Uk Ltd
Original Assignee
Rb Pharmaceutical Co ltd
Torma Medical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39496214&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101801415(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rb Pharmaceutical Co ltd, Torma Medical Co ltd filed Critical Rb Pharmaceutical Co ltd
Publication of CN101801415A publication Critical patent/CN101801415A/zh
Application granted granted Critical
Publication of CN101801415B publication Critical patent/CN101801415B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN200880100394.0A 2007-05-25 2008-02-13 利培酮化合物的持续递送制剂 Expired - Fee Related CN101801415B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94034007P 2007-05-25 2007-05-25
US60/940,340 2007-05-25
PCT/US2008/001928 WO2008153611A2 (en) 2007-05-25 2008-02-13 Sustained delivery formulations of risperidone compounds

Publications (2)

Publication Number Publication Date
CN101801415A CN101801415A (zh) 2010-08-11
CN101801415B true CN101801415B (zh) 2015-09-23

Family

ID=39496214

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880100394.0A Expired - Fee Related CN101801415B (zh) 2007-05-25 2008-02-13 利培酮化合物的持续递送制剂

Country Status (11)

Country Link
US (7) US10010612B2 (enExample)
EP (2) EP2152315B1 (enExample)
JP (3) JP2010531807A (enExample)
CN (1) CN101801415B (enExample)
AU (1) AU2008262545B2 (enExample)
BR (1) BRPI0811319A2 (enExample)
CA (1) CA2687979C (enExample)
ES (1) ES2562878T3 (enExample)
MX (2) MX337286B (enExample)
NZ (2) NZ597621A (enExample)
WO (1) WO2008153611A2 (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
CN101653422B (zh) * 2008-08-20 2013-03-20 山东绿叶制药有限公司 利培酮缓释微球、其制备方法和用途
CN101584652B (zh) * 2009-06-19 2012-06-20 上海医药集团股份有限公司 利培酮缓释凝胶注射剂及其制备方法
US20130053405A1 (en) 2009-10-06 2013-02-28 Ulrich Hersel Carrier linked paliperidone prodrugs
US8758780B2 (en) 2009-10-06 2014-06-24 Ascendis Pharma As Subcutaneous paliperidone composition
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
EP2529756B1 (en) 2011-05-31 2021-05-19 Laboratorios Farmaceuticos Rovi, S.A. Risperidone and/or Paliperidone implant formulation
EP2394664B1 (en) * 2010-05-31 2016-06-01 Laboratorios Farmaceuticos Rovi, S.A. Antipsychotic injectable depot composition
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
SI2394663T1 (sl) 2010-05-31 2022-02-28 Laboratorios Farmaceuticos Rovi, S.A. Sestave za injicirane biološko razgradljive vsadke in situ
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
CN105748402B (zh) * 2010-11-24 2022-06-03 杜雷科特公司 生物可降解的药物递送组合物
CN102058517A (zh) * 2010-12-31 2011-05-18 泰州万全医药科技有限公司 一种帕潘立酮缓释剂及其制备方法
HUE066287T2 (hu) 2011-04-25 2024-07-28 Geneora Pharma Shijiazhuang Co Ltd Nyújtott leadású mikroszféra risperidon készítmény
SI2529757T1 (sl) * 2011-05-31 2014-05-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija paliperidon implantata
DE102013011399A1 (de) 2012-07-31 2014-02-06 Amw Gmbh Implantat mit Risperidon
CA2885941A1 (en) * 2012-09-28 2014-04-03 Delpor, Inc. Device and method for sustained release of antipsychotic medications
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
WO2014164754A1 (en) 2013-03-11 2014-10-09 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
MX2016016406A (es) 2014-06-11 2017-10-12 Massachusetts Inst Technology Estructuras de permanencia, y métodos relacionados.
US20160128997A1 (en) 2014-11-07 2016-05-12 Indivior Uk Limited Sustained-release buprenorphine formulations
CN104398474A (zh) * 2014-11-21 2015-03-11 内蒙古医科大学附属医院 一种利培酮鼻用凝胶剂及其制备方法
WO2016178971A1 (en) 2015-05-01 2016-11-10 Massachusetts Institute Of Technology Triggerable shape memory induction devices
US20170079985A1 (en) 2015-09-21 2017-03-23 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
US20190015415A1 (en) * 2015-09-30 2019-01-17 Indivior Uk Limited Methods for treating schizophrenia
AU2016342374B2 (en) 2015-10-23 2022-08-04 Nortiva Bio, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
AU2016355236C1 (en) 2015-11-16 2022-09-22 Medincell A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
KR102796240B1 (ko) 2015-12-08 2025-04-16 린드라 테라퓨틱스 인코퍼레이티드 위 체류 시스템을 위한 기하 구성형태
WO2017119928A1 (en) * 2016-01-08 2017-07-13 Abon Pharmaceuticals, Llc Long acting injectable formulations
US12109305B2 (en) 2016-05-27 2024-10-08 Lyndra Therapeutics, Inc. Materials architecture for gastric residence systems
EP3518902A4 (en) 2016-09-30 2020-07-08 Lyndra, Inc. GASTRIC RESIDENCE SYSTEMS FOR LONG-TERM ADMINISTRATION OF ADAMANTANE CLASS MEDICINES
AU2017391591B2 (en) * 2017-01-04 2022-12-22 Pharmathen S.A. Process for preparing biodegradable polymers of high molecular weight
US20180235899A1 (en) 2017-02-17 2018-08-23 Privo Technologies, Inc. Particle-based multi-layer therapeutic delivery device and method
EP3600258A1 (en) 2017-03-20 2020-02-05 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulaitons
US10478403B1 (en) 2017-05-03 2019-11-19 Privo Technologies, Inc. Intraoperative topically-applied non-implantable rapid release patch
TWI811221B (zh) 2017-06-09 2023-08-11 美商萊恩卓治療公司 具有釋放速率調節膜之胃的滯留系統
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
TWI768124B (zh) * 2017-09-20 2022-06-21 日商花王股份有限公司 染毛方法
US20190117573A1 (en) * 2017-10-19 2019-04-25 Hyalo Technologies, LLC Composition and method of preparation of risperidone extended release preparation
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
CA3087238A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
CN111989068B (zh) 2018-05-24 2024-10-25 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
PE20210047A1 (es) 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
US20210386745A1 (en) * 2019-01-22 2021-12-16 Indivior Uk Limited Methods for treating schizophrenia
SI4027973T1 (sl) 2019-09-13 2026-02-27 Medincell S.A. Formulacije za dostavo zdravil
WO2021113514A1 (en) * 2019-12-05 2021-06-10 Fresenius Kabi Usa, Llc Method for analyzing degarelix and associated products
WO2021138646A1 (en) * 2020-01-03 2021-07-08 Privo Technologies, Inc. Systems and pharmaceutical compositions for treatment by direct injection of a targeted population of cells
WO2022069996A1 (en) * 2020-09-30 2022-04-07 Tolmar International Limited Biodegradable polymer and solvent compositions and systems for extended storage and delivery of active pharmaceutical ingredients
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
EP4329734A4 (en) 2021-04-26 2025-04-02 Celanese EVA Performance Polymers LLC Implantable device for the delayed release of a macromolecular drug compound
CN113267579B (zh) * 2021-05-18 2022-08-30 中南民族大学 一种监测利培酮血药浓度的方法
KR20240041285A (ko) 2021-06-01 2024-03-29 프리보 테크놀로지스, 인코포레이티드 향상된 2단계 미세입자 기반 국소 치료제 전달 시스템
CA3218153A1 (en) * 2021-06-30 2023-01-05 Soumya Rahima BENHABBOUR Injectable, biodegradable and removable polymer based drug suspension for ultra-long-acting drug delivery
EP4366726A1 (en) 2021-07-06 2024-05-15 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
US12594236B2 (en) 2021-07-16 2026-04-07 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物
WO2023233051A1 (es) 2022-05-18 2023-12-07 Laboratorios Farmacéuticos Rovi, S.A. Composiciones inyectables de liberación prolongada para su uso en el tratamiento con risperidona junto a inhibidores de la enzima cyp2d6
TW202523334A (zh) * 2023-12-13 2025-06-16 大陸商長春金賽藥業有限責任公司 原位皮下植入的女性激素調節組合物及其製備方法和用途
CN119950530B (zh) * 2025-01-24 2025-12-05 山东新时代药业有限公司 一种包含他莫昔芬与人参皂苷的纳米乳及其制备方法

Family Cites Families (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB806876A (en) 1956-02-16 1959-01-07 Wellcome Found Improvements in and relating to disposable hypodermic injection devices
GB873526A (en) 1957-08-14 1961-07-26 Upjohn Co Fluid compositions comprising (acetyl-salicylic acid)-anhydride
GB887872A (en) 1958-06-25 1962-01-24 Upjohn Co Improvements in or relating to pharmaceutical preparations
DE1467938C3 (de) 1964-05-22 1973-12-20 F. Hoffmann-La Roche & Co Ag, Basel (Schweiz) Wasserdispergierbares Arzneipräparat für Tiere
JPS5078634A (enExample) 1973-11-16 1975-06-26
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4622219A (en) 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4891225A (en) 1984-05-21 1990-01-02 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4588580B2 (en) 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4534974A (en) 1984-07-31 1985-08-13 Carter-Wallace, Inc. Pharmaceutical compositions with codeine
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4573995A (en) 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
GB8522453D0 (en) 1985-09-11 1985-10-16 Lilly Industries Ltd Chewable capsules
JPS62298530A (ja) 1986-06-16 1987-12-25 Otsuka Pharmaceut Co Ltd 坐薬用医薬組成物
IT1198449B (it) 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
CA2002299A1 (en) 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
US5026556A (en) 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5487897A (en) 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
DE3927113C2 (de) 1989-08-17 1993-11-25 Dolorgiet Gmbh & Co Kg Mittel zur Behandlung von schweren Schmerzzuständen und Verfahren zu ihrer Herstellung
US5096715A (en) 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
US5558880A (en) 1989-12-22 1996-09-24 Janssen Pharmaceutica Inc. Pharmaceutical and other dosage forms
US5660851A (en) 1989-12-26 1997-08-26 Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem Ocular inserts
DK0532546T3 (da) 1990-05-10 1998-12-28 Nycomed Pharma As Farmaceutisk præparat indeholdende N-glycofuroler og N-ethylenglycoler
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
JPH0456736U (enExample) 1990-09-14 1992-05-15
US5149543A (en) 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
ATE183639T1 (de) 1991-02-18 1999-09-15 Commw Scient Ind Res Org Zusammensetzung zur verwendung in der transdermalen verabreichung
JP3145742B2 (ja) 1991-09-19 2001-03-12 日東電工株式会社 ゴム系感圧性接着剤とその接着シ―ト
AU2605592A (en) 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
WO1993023019A1 (en) 1992-05-11 1993-11-25 Sri International Transdermal drug delivery systems and related compositions and methods of use
EP0669128B1 (en) 1992-11-17 2000-01-05 Yoshitomi Pharmaceutical Industries, Ltd. Sustained-release microsphere containing antipsychotic and process for producing the same
TW376319B (en) 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
JP2651106B2 (ja) 1993-06-28 1997-09-10 大同鋼板株式会社 金属屋根材の葺設構造及びその葺設方法
NZ260909A (en) 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
US5643605A (en) 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
ATE288270T1 (de) 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
ATE212830T1 (de) 1993-11-19 2002-02-15 Alkermes Inc Herstellung biologisch abbaubarer, einen biologisch aktiven stoff enthaltender, mikropartikel
EP1125577B1 (en) 1994-04-08 2006-02-15 QLT USA, Inc. Liquid drug delivery compositions
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
AU4652596A (en) 1995-01-09 1996-07-31 Atrix Laboratories, Inc. Liquid polymer delivery system
JP3274579B2 (ja) 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤
EP1525858A1 (en) 1995-06-07 2005-04-27 Durect Corporation High viscosity liquid controlled delivery system
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6004969A (en) 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
ES2183172T3 (es) 1996-05-07 2003-03-16 Alkermes Inc Procedimiento para la preparacion de microparticulas.
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
JP4346696B2 (ja) 1996-05-28 2009-10-21 久光製薬株式会社 経皮治療用装置
EP0910345B1 (en) 1996-06-17 2002-02-13 Janssen Pharmaceutica N.V. Biconvex rapidly disintegrating dosage forms
ATE318580T1 (de) 1996-12-20 2006-03-15 Alza Corp Gelzusammensetzungen und verfahren
DE19701912C1 (de) 1997-01-10 1998-05-14 Jenapharm Gmbh Injizierbares Implantat
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
IT1292396B1 (it) 1997-06-23 1999-02-08 Lisapharma Spa Cerotto dermico avente elevata resistenza meccanica,flessibilita' trasparenza e conducibilita' elettrica nel trattamento di affezioni
US6622036B1 (en) 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
DE69916911T2 (de) 1998-02-10 2005-04-21 Gen Electric Brenner mit gleichmässiger Brennstoff/Luft Vormischung zur emissionsarmen Verbrennung
US6733767B2 (en) 1998-03-19 2004-05-11 Merck & Co., Inc. Liquid polymeric compositions for controlled release of bioactive substances
US7208011B2 (en) 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US6261583B1 (en) 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6703047B2 (en) 2001-02-02 2004-03-09 Incept Llc Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6355657B1 (en) 1998-12-30 2002-03-12 Atrix Laboratories, Inc. System for percutaneous delivery of opioid analgesics
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6291013B1 (en) 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
DE19923551A1 (de) 1999-05-21 2000-11-30 Lohmann Therapie Syst Lts Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
DE50112157D1 (de) 2000-01-11 2007-04-19 Roland Bodmeier Kit zur implantation enthaltend eine trägerphase und ein lösungsmittel
KR100393478B1 (ko) 2000-03-29 2003-08-06 주식회사종근당 자가유화 매트릭스형 경점막·경피흡수제제
ATE264329T1 (de) 2000-05-05 2004-04-15 Rpg Life Sciences Ltd Verfahren zur herstellung von antipsychotischem 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
JP2004511431A (ja) 2000-06-28 2004-04-15 アトゥル・ジェイ・シュクラ 生物活性物質を含む生分解性ビヒクルおよび送達システム
DE10035889A1 (de) 2000-07-24 2002-02-14 Lohmann Therapie Syst Lts Medizinischer Haftkleber mit einem Gehalt an Zucker-Estern
ATE401313T1 (de) 2000-08-14 2008-08-15 Teva Pharma Herstellung von risperidon
DE10044545A1 (de) 2000-09-05 2002-04-04 Roland Bodmeier Retardpartikeldispersion
IT250575Y1 (it) 2000-10-10 2003-09-24 Gimatic Spa Sistema di guida registrabile per griffe di pinze azionate da unfluido
WO2002038185A2 (en) 2000-11-13 2002-05-16 Atrix Laboratories, Inc. Injectable sustained release delivery system with loperamide
EP1335704A2 (en) 2000-11-16 2003-08-20 Durect Corporation Implant dosage form and use thereof for the delivery of a cholesterol lowering agent
DE60231862D1 (de) 2001-02-23 2009-05-20 Genentech Inc Erodierbare polymere zur injektion
US20040018238A1 (en) 2001-02-26 2004-01-29 Shukla Atul J Biodegradable vehicles and delivery systems of biolgically active substances
WO2002076344A1 (en) 2001-03-23 2002-10-03 Durect Corporation Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
US6558702B2 (en) * 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
GB0112324D0 (en) 2001-05-21 2001-07-11 Croda Int Plc Compounds
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
JP2003063954A (ja) 2001-08-24 2003-03-05 Saitama Daiichi Seiyaku Kk リザーバー型貼付剤
ATE507816T1 (de) 2001-11-14 2011-05-15 Durect Corp Injizierbare depotzusammensetzungen und deren verwendung
NZ533434A (en) 2001-11-14 2006-11-30 Alza Corp Thixotropic gel composition for injectable deposition
AU2002359407B2 (en) 2001-11-14 2008-02-28 Durect Corporation Catheter injectable depot compositions and uses thereof
US20040258731A1 (en) 2001-11-21 2004-12-23 Tsuyoshi Shimoboji Preparation approriate for cartilage tissue formation
NZ535270A (en) 2002-03-12 2006-11-30 Univ Montreal Composition having gelling properties for the sustained delivery of bioactive substances
US7041320B1 (en) 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
TWI314464B (en) 2002-06-24 2009-09-11 Alza Corp Reusable, spring driven autoinjector
TWI353854B (en) 2002-06-25 2011-12-11 Alza Corp Short duration depot formulations
US20040003401A1 (en) 2002-06-27 2004-01-01 Koninklijke Philips Electronics N.V. Method and apparatus for using cluster compactness as a measure for generation of additional clusters for stereotyping programs
CN1684663A (zh) 2002-07-31 2005-10-19 阿尔萨公司 可注射的多模式聚合物储库组合物以及其用途
AU2003257994A1 (en) 2002-07-31 2004-02-16 Alza Corporation Injection device providing automatic needle retraction
AU2003256006A1 (en) 2002-08-30 2004-03-19 Sunil Sadanand Nadkarni Improved process for preparation of risperidone
CA2500908A1 (en) 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
KR20040034996A (ko) 2002-10-18 2004-04-29 한미약품 주식회사 리스페리돈의 개선된 제조방법
EP1575616A2 (en) 2002-10-25 2005-09-21 Pfizer Products Inc. Novel injectable depot formulations
DE10250084A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US7368126B2 (en) 2002-11-06 2008-05-06 Guohua Chen Controlled release depot formulations
EP2218448B1 (en) 2002-12-13 2015-09-23 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
WO2004071491A1 (en) 2003-02-04 2004-08-26 Chrysalis Technologies Incorporated Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
WO2004094415A1 (en) 2003-04-22 2004-11-04 Synthon B.V. Risperidone monohydrochloride
US20050079202A1 (en) 2003-05-30 2005-04-14 Guohua Chen Implantable elastomeric depot compositions and uses thereof
ATE410186T1 (de) 2003-06-26 2008-10-15 Control Delivery Sys Inc In-situ gelierendes arzneimittelabgabesystem
TWI357815B (en) 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
FI20045223L (fi) 2004-06-15 2005-12-16 Bioretec Oy Monitoiminen biohajoava komposiitti ja kirurginen implantti, joka käsittää mainitun komposiitin
US20050032781A1 (en) * 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP 2D6 sensitive patients
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
WO2005021046A1 (en) 2003-09-01 2005-03-10 Fh Faulding & Co Ltd Compositions and methods for delivery of biologically active agents
WO2005037949A2 (en) 2003-10-07 2005-04-28 Chrysalis Technologies Incorporated Aerosol formulations of butalbital, lorazepam, ipratropium, baclofen, morphine and scopolamine
US20070191815A1 (en) 2004-09-13 2007-08-16 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
US20050281879A1 (en) 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
US20050106214A1 (en) 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
EP1689465A4 (en) 2003-12-05 2011-10-12 Zogenix Inc DEVICE FOR DELIVERY OF A NEEDLELESS INJECTOR USED FOR DRUG DELIVERY
CA2552241C (en) 2003-12-30 2013-10-01 Durect Corporation Co-polymeric devices for controlled release of active agents
US8329203B2 (en) 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
KR101242486B1 (ko) 2004-01-12 2013-03-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 장기 전달을 위한 제형 및 그의 이용 방법
WO2005089670A1 (en) 2004-03-15 2005-09-29 Durect Corporation Pharmaceutical compositions for administration to a sinus
IS7290A (is) 2004-05-28 2005-11-29 Actavis Group Lyfjasamsetningar sem innihalda risperidone
PL1768650T3 (pl) 2004-06-04 2009-01-30 Camurus Ab Ciekłe formulacje depot
EP1604693A1 (en) 2004-06-09 2005-12-14 Scil Technology GmbH In situ forming scaffold, its manufacturing and use
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
CA2582374A1 (en) 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
ATE551995T1 (de) 2004-10-21 2012-04-15 Durect Corp Transdermale abgabesysteme
EP1824460B1 (en) 2004-11-10 2014-12-24 Tolmar Therapeutics, Inc. A stabilized polymeric delivery system
GB2420976B (en) 2004-11-19 2006-12-20 Zvi Finkelstein Therapeutic implant
AR052155A1 (es) 2004-12-14 2007-03-07 Novartis Ag Compuestos organicos
WO2006065951A2 (en) 2004-12-15 2006-06-22 Qlt Usa, Inc. Sustained delivery formulations of octreotide compounds
WO2006063430A1 (en) 2004-12-16 2006-06-22 Miv Therapeutics Inc. Multi-layer drug delivery device and method of manufacturing same
US9415034B2 (en) 2005-01-05 2016-08-16 National Defense Medical Center Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B)
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
JP5405825B2 (ja) 2005-07-18 2014-02-05 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 薬剤含有インプラント及びその使用方法
US20070020186A1 (en) 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
WO2007017712A1 (en) 2005-08-11 2007-02-15 Promedon Do Brasil Produtos Medico-Hospitalares Ltda. Composition comprising polymeric, water-insoluble, anionic particles, processes and uses
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
JP5406530B2 (ja) 2005-10-26 2014-02-05 バナー ファーマキャプス， インコーポレイテッド 親水性ベヒクルに基づく二重制御された放出マトリクスシステム
CA2637569C (en) 2006-01-18 2013-01-08 Yuhua Li Pharmaceutical compositions with enhanced stability
US20090022798A1 (en) 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US8765178B2 (en) 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
ATE492192T1 (de) 2006-09-25 2011-01-15 Koninkl Philips Electronics Nv Heisswasserkessel mit einem akustischen element zur erzeugung eines akustischen signals
HUE038022T4 (hu) 2006-10-02 2023-02-28 Spepharm Ag Nem mukoadhezív filmdózisformák
US20100098735A1 (en) 2006-10-05 2010-04-22 Rajesh Jain Injectable depot compositions and its process of preparation
EP2079767B1 (en) * 2006-10-11 2014-08-27 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
US8076448B2 (en) 2006-10-11 2011-12-13 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
GB0620661D0 (en) 2006-10-18 2006-11-29 Pharmasol Ltd Novel compounds
EP3202814B1 (en) 2007-02-15 2019-10-16 Tolmar Therapeutics, Inc. Low burst poly-(lactide/glycolide) and methods to produce polymers
KR101612901B1 (ko) 2007-03-02 2016-04-15 테이카 세이야쿠 가부시키가이샤 경피흡수 의약조성물, 의약조성물 저장유닛 및 이것을 이용하는 경피흡수제제
CN101678125A (zh) 2007-04-03 2010-03-24 特里梅里斯公司 用于递送抗病毒肽治疗剂的新制剂
CN101677952B (zh) 2007-05-18 2012-12-05 杜雷科特公司 改进的贮库制剂
EP2152315B1 (en) * 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
HUE027537T2 (en) 2007-09-03 2016-10-28 Nanotherapeutics Inc Granular preparations for the administration of poorly soluble drugs
HRP20191104T1 (hr) 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
EP2067471B1 (en) 2007-12-06 2018-02-14 Durect Corporation Oral pharmaceutical dosage forms
FR2926996B1 (fr) 2008-01-31 2013-06-21 Ethypharm Sa Composition pharmaceutique a proprietes gelifiantes contenant un derive de tyrosine
EP2254559B1 (en) 2008-02-08 2018-10-10 Foresee Pharmaceuticals Co., Ltd. Composition for sustained release delivery of proteins or peptides
WO2009100222A1 (en) 2008-02-08 2009-08-13 Qps Llc Non-polymeric compositions for controlled drug delivery
JP5286850B2 (ja) 2008-03-14 2013-09-11 大日本印刷株式会社 液体用紙容器用包装材料およびその包装材料から製造される液体用紙容器
CA2718943A1 (en) 2008-03-26 2009-10-01 Alltranz Inc. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
US8877225B2 (en) 2008-06-03 2014-11-04 Tolmar Therapeutics, Inc. Controlled release copolymer formulation with improved release kinetics
DK2291174T3 (en) 2008-06-03 2015-03-09 Tolmar Therapeutics Inc Liquid compositions comprising biocompatible oligomer-polymer compositions
US8128951B2 (en) 2008-09-15 2012-03-06 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8257722B2 (en) 2008-09-15 2012-09-04 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8114429B2 (en) 2008-09-15 2012-02-14 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
CA2756879A1 (en) 2009-04-23 2010-10-28 Londonpharma Ltd. Sublingual pharmaceutical composition comprising a neutral oil
RU2567032C2 (ru) 2009-05-01 2015-10-27 Апталис Фарматек, Инк. Перорально распадающиеся таблеточные композиции, содержащие комбинации неопиоидных и опиоидных анальгетиков
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
FR2949061B1 (fr) 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
CA2780645C (en) 2009-11-18 2018-01-16 Nektar Therapeutics Salt form of a multi-arm polymer-drug conjugate
US20130023553A1 (en) 2010-01-12 2013-01-24 Nektar Therapeutics Pegylated opioids with low potential for abuse and side effects
BR112012023303A2 (pt) 2010-03-15 2020-08-25 Ipsen Pharma S.A.S. composição farmacêutica de ligantes do receptor do secretagogo do hormônio de crescimento.
US20110230816A1 (en) 2010-03-18 2011-09-22 Tyco Healthcare Group Lp Gels for Transdermal Delivery
EP2394664B1 (en) 2010-05-31 2016-06-01 Laboratorios Farmaceuticos Rovi, S.A. Antipsychotic injectable depot composition
EP2529756B1 (en) 2011-05-31 2021-05-19 Laboratorios Farmaceuticos Rovi, S.A. Risperidone and/or Paliperidone implant formulation
SI2394663T1 (sl) 2010-05-31 2022-02-28 Laboratorios Farmaceuticos Rovi, S.A. Sestave za injicirane biološko razgradljive vsadke in situ
WO2011161531A1 (en) 2010-06-24 2011-12-29 Torrent Pharmaceuticals Limited Pharmaceutical composition containing goserelin for in-situ implant
ME02367B (me) 2010-09-21 2016-06-20 Purdue Pharma Lp Analozi buprenorfina kao agonisti i/ili antagonisti opioidnog receptora
CA2815898C (en) 2010-11-17 2018-12-18 Hexal Ag Transdermal therapeutic system comprising buprenorphine
CN105748402B (zh) 2010-11-24 2022-06-03 杜雷科特公司 生物可降解的药物递送组合物
US20140023692A1 (en) 2010-11-26 2014-01-23 Lisa Claire Du Toit Drug delivery device
EA201491164A1 (ru) 2011-12-12 2014-10-30 ЭлТиЭс ЛОМАНН ТЕРАПИ-ЗЮСТЕМ АГ Трансдермальная система доставки
US9468599B2 (en) 2011-12-27 2016-10-18 Cmpd Licensing, Llc Composition and method for compounded therapy
US20140134261A1 (en) 2012-08-21 2014-05-15 Trinity Laboratories, Inc. Pharmaceutical Compositions Comprising Capsaicin Esters for Treating Pain and Cold Sores
RU2513514C1 (ru) 2012-11-23 2014-04-20 Общество с ограниченной ответственностью "НПК "Трифарма" Фармацевтическая композиция, содержащая налбуфина гидрохлорид, ее применение для лечения болевого синдрома средней и высокой интенсивности и способ получения фармацевтической композиции
CN103142458B (zh) 2013-01-22 2015-09-09 莱普德制药有限公司 无成瘾性镇痛缓释递药系统的组方与制备方法
WO2014164754A1 (en) 2013-03-11 2014-10-09 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US20160303038A1 (en) 2013-11-21 2016-10-20 Pawar Harshal Ashok Oral films
US10525171B2 (en) 2014-01-24 2020-01-07 The Spectranetics Corporation Coatings for medical devices

Also Published As

Publication number Publication date
US20150099767A1 (en) 2015-04-09
JP5795606B2 (ja) 2015-10-14
US11013809B2 (en) 2021-05-25
US11712475B2 (en) 2023-08-01
CN101801415A (zh) 2010-08-11
HK1143731A1 (zh) 2011-01-14
US20200016270A1 (en) 2020-01-16
WO2008153611A2 (en) 2008-12-18
US9180197B2 (en) 2015-11-10
JP2014240436A (ja) 2014-12-25
US9186413B2 (en) 2015-11-17
US20220354955A1 (en) 2022-11-10
NZ581862A (en) 2012-06-29
JP2013139479A (ja) 2013-07-18
US20100266655A1 (en) 2010-10-21
US10376590B2 (en) 2019-08-13
US20150005323A1 (en) 2015-01-01
CA2687979A1 (en) 2008-12-18
MX2009012781A (es) 2010-07-02
US20230135427A1 (en) 2023-05-04
ES2562878T3 (es) 2016-03-08
NZ597621A (en) 2013-06-28
AU2008262545B2 (en) 2013-12-05
AU2008262545A1 (en) 2008-12-18
US10010612B2 (en) 2018-07-03
EP2152315A2 (en) 2010-02-17
MX354603B (es) 2018-03-13
US20180154001A1 (en) 2018-06-07
EP2152315B1 (en) 2016-01-06
BRPI0811319A2 (pt) 2015-02-10
MX337286B (es) 2016-02-22
WO2008153611A3 (en) 2009-07-16
JP2010531807A (ja) 2010-09-30
EP2907524A1 (en) 2015-08-19
CA2687979C (en) 2017-07-04

Similar Documents

Publication Publication Date Title
US11712475B2 (en) Sustained delivery formulations of risperidone compound
EP3360538B1 (en) Injectable flowable composition comprising buprenorphine
US10592168B1 (en) Injectable flowable composition comprising buprenorphine
JP2010531807A5 (enExample)
HK40097172A (en) Injectable flowable composition comprising buprenorphine
HK1143731B (en) Sustained delivery formulations of risperidone compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: RB MEDICAL LTD.

Free format text: FORMER OWNER: TOLMAR THERAPEUTICS INC.

Effective date: 20140523

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20140523

Address after: Burke County, England

Applicant after: RECKITT BENCKISER HEALTHCARE (UK) LIMITED

Address before: American Colorado

Applicant before: Tolmar Therapeutics Inc.

C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: Burke County, England

Patentee after: The British Virgin UK Ltd

Address before: Burke County, England

Patentee before: RECKITT BENCKISER HEALTHCARE (UK) LIMITED

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150923

Termination date: 20190213